Cubist stops R&D on cardiac surgery drug
Cubist Pharmaceuticals is planning to stop investing in the clinical development of CB-500,929 (ecallantide) as a therapy to reduce blood loss in patients undergoing cardiac surgery using cardiopulmonary bypass.

The Lexington, Mass.-based company said it made the decision after reviewing the efficacy and safety data from the CB-500,929 Phase 2 CONSERV 1 and CONSERV 2 trials. “This decision does not impact the 2010 R&D cost guidance announced by the company in January 2010 as the guidance did not include costs for potential development of CB-500,929 beyond the CONSERV trials,” the company added.

Given its decision to end the development of CB-500,929, Cubist also said it intends to terminate the 2008 agreement with Dyax under which Cubist in-licensed development and commercialization rights to CB-500,929 for surgical indications in the U.S. and the European Union, in accordance with the terms of the agreement.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup